Trevi Therapeutics announced the commencement of an underwritten public offering of $100,000,000 of shares of its common stock. All shares in the offering are being sold by Trevi.
The company expects to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of common stock at the public offering price. The offering is subject to market and other conditions.
This financing initiative aims to secure substantial capital to support the ongoing and future clinical development of Haduvio for chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.